

A

09/473619
10739/99

Patents, Washington, D.C. 20231.

WASHINGTON, DC

FISH & RICHARDSON P.C.

December 29, 1999

Page 2

In addition to the above-listed pages, the following items are also enclosed herewith:

- Preliminary Amendment
- Copy of Verified Statement (Declaration) Claiming Small Entity Status
- Copy of Information Disclosure Statement filed April 29, 1998 in the parent application (to be entered into this application).
- Form PTO-1449 listing documents cited in the parent application(s). (Please confirm that these have been considered in this application by returning a copy of the Form PTO-1449 with the examiner's initials.)
- Sequence Listing Verification Statement, 2 pages.
- Return Postcard.

The present application is entitled to small entity status. Small entity status from the parent application is still proper. Applicant requests consideration of the enclosed preliminary amendment prior to calculation of the filing fee. The filing fee has been calculated as follows:

Basic filing fee	345.00
Total claims in excess of 20 times \$9.00	243.00
Independent claims in excess of 3 times \$39.00	312.00
Fee for multiple dependent claims	130.00
Total filing fee:	1030.00

A check for the filing fee is enclosed. Please apply any other required fees or any credits to deposit account 06-1050, referencing the attorney docket number shown above.

Please send all correspondence to:

Gary L. Creason
Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110-2804

FISH & RICHARDSON P.C.

December 29, 1999

Page 3

If this application is found to be incomplete, or if a telephone conference would otherwise be helpful, please call the undersigned at 617/542-5070. Kindly acknowledge receipt of this application by returning the enclosed postcard.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Gary L. Creason". The signature is fluid and cursive, with the first name "Gary" being more prominent.

Gary L. Creason
Reg. No. 34,310

Enclosures

405211.B11

405211.B11

Applicant or Patentee: Robert Siman; Donna Bozyczko-Coyne; Sheryl L. Meyer; Ratan Venkatraman Bhat

Serial No.: 08/967,625 Attorney's Docket No.: CEPH-0425

Date Filed: November 12, 1997

For: METHODS FOR DETECTING CELL APOPTOSIS

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(d) and 1.27(c)) - SMALL BUSINESS CONCERN

I hereby declare that I am:

- () the owner of the small business concern identified below:
(XX) an official empowered to act on behalf of the concern identified below:

NAME OF CONCERN: Cephalon, Inc.
ADDRESS OF CONCERN: 145 Brandywine Parkway
West Chester, PA 19380

I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 CFR 121.12, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, in that: (1) the number of employees of the concern, including those of its affiliates, does not exceed 500 persons; and (2) the concern has not assigned, granted, conveyed, or licensed, and is under no obligation under contract or law to assign, grant, convey, or license, any rights in the invention to any person who could not be classified as an independent inventor if that person had made the invention, or to any concern which would not qualify as a small business concern or a nonprofit organization under this section. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention entitled METHODS FOR DETECTING CELL APOPTOSIS by inventor(s) Robert Siman; Donna Bozyczko-Coyne; Sheryl L. Meyer; and Ratan Venkatraman Bhat described in

() specification filed herewith.

(XX) application serial no. 08/967,625, filed November 12, 1997

() patent no. _____, issued _____.

If the rights held by the above-identified small business concern are not exclusive, each individual, concern or organization having rights in the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e).

*NOTE: Separate verified statements are required for each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

FULL NAME: @@

ADDRESS: @@

() INDIVIDUAL () SMALL BUSINESS CONCERN () NONPROFIT ORGANIZATION

FULL NAME: @@

ADDRESS: @@

() INDIVIDUAL () SMALL BUSINESS CONCERN () NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING Barbara S. Schilberg
TITLE OF PERSON SIGNING Senior Vice President, General Counsel and Secretary
ADDRESS OF PERSON SIGNING 145 Brandywine Parkway
West Chester, PA 19380

Barbara S. Schilberg
SIGNATURE

January 12, 1998
DATE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Robert Siman et al. Art Unit:
Serial No.: Examiner:
Filed : December 29, 1999
Title : METHODS FOR DETECTING CELL APOPTOSIS

Assistant Commissioner for Patents
Washington, DC 20231

PRELIMINARY AMENDMENT

Prior to examination of the above-identified
application, please amend the application as follows:

In the claims:

Cancel claims 8 and 12.

Add new claims 44, 45 and 46:

--44. (New) The method of claim 7 or 11, wherein said
protein fragments are produced from poly-ADP-ribose polymerase.

45. (New) The method of claim 44, wherein said
protease cleavage products are produced by a protease selected
from the group consisting of ICE, CPP32/apopain/Yama, ICH-1,
TX/ICH-2/ICE_{rel}III, ICE_{rel}III, MH-1/MH-3/ICE-LAP3, Mch2,
FLICE/Mch5, and ICE-LAP6/Mch6.

"EXPRESS MAIL" Mailing Label Number EL445348851US

Date of Deposit December 29, 1999

I hereby certify under 37 CFR 1.10 that this correspondence is being
deposited with the United States Postal Service as "Express Mail
Post Office To Addressee" with sufficient postage on the date
indicated above and is addressed to the Assistant Commissioner for
Patents, Washington, D.C. 20231.

Samantha Bell
Samantha Bell

46. (New) The method of claim 7 or 11, wherein said protein fragments are produced from DNA replication complex C, DNA-dependent protein kinase, protein kinase of presenilin 1 and 2, or spectrin.--

Remarks

Support for new claim 44 appears in the specification, for example, at page 10, line 5 to page 11, line 1. Support for new claim 45 appears in the specification, for example, at page 3, lines 14-24. Support for new claim 46 appears in the specification, for example, at page 10, lines 18-23.

Conclusion

Applicant submits that the claims are now in condition for allowance. Such action is requested. If the Examiner finds that a telephone conference would advance prosecution, the

examiner is invited to telephone the undersigned at the number provided below.

Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: 29 DEC 1999

Gary L. Creason
Gary L. Creason
Reg. No. 34,310

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110-2804

Telephone: 617/542-5070
Facsimile: 617/542-8906
406042.B11

APPLICATION
FOR
UNITED STATES LETTERS PATENT

TITLE: METHODS FOR DETECTING CELL APOPTOSIS

APPLICANT: ROBERT SIMAN
DONNA BOZYCZKO-COYNE
SHERYL L. MEYER
RATAN VENKATRAMAN BHAT

"EXPRESS MAIL" Mailing Label Number **EL445348851US**

Date of Deposit **December 29, 1999**

I hereby certify under 37 CFR 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office To Addressee" with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Samantha Bell
Samantha Bell

METHODS FOR DETECTING CELL APOPTOSIS

Cross-Reference To Related Applications

This patent application claims priority under 35 U.S.C. § 119(e) to provisional patent application Serial No. 60/030,961, filed November 15, 1996, hereby
5 incorporated in its entirety by reference.

Field of the Invention

The present invention is directed to the detection and quantification of cell apoptosis. More particularly, the present invention is directed to the detection of cell apoptosis by using specific antibodies to detect cells undergoing apoptosis and cells
10 which have undergone apoptotic cell death.

Background of the Invention

Apoptosis is a physiological mechanism of cell death which involves the fragmentation of a cell into membrane-bound particles. The process of apoptosis is involved in a variety of normal and pathogenic biological events, both during
15 development and in adulthood. Agents which affect apoptosis may have therapeutic utility in treating diseases and disorders characterized by aberrant cell proliferation or death (reviewed in Hoepfner et al., Biochim. Biophys. Acta 1242: 217-220, 1996; Thompson, Science 267:1456-1462, 1995). Techniques for detection of apoptosis may be useful to screen for potential therapeutic agents that may induce or prevent
20 apoptosis.

In view of the biological importance of apoptosis, there exists a need for methods to specifically detect cells undergoing apoptosis and those which have suffered apoptotic cell death. These methods are crucial to the identification, characterization, and diagnosis of diseases distinguished by abnormal apoptosis, and to the screening of potential therapeutic agents that may induce or prevent apoptosis.

Several methods are known for the detection of apoptosis *in vitro* and *in vivo*, but these have significant drawbacks which limit their utility. Commonly, apoptosis is characterized by condensation and margination of nuclear chromatin, and fragmentation of nuclear structure into so-called apoptotic bodies. This apoptotic morphology can be observed using conventional stains, dyes which selectively accumulate in nuclei such as propidium iodide or Hoechst 33258, or by electron microscopy (e.g., Nicoletti et al., J. Immunol. Methods 139:271-279 1991; Crompton et al., Biochem. Biophys. Res. Commun. 183:532-537 1992; Frey, Cytometry 21:265-274 1995; Woo, N. Engl. J. Med. 333:18-25 1995). Unfortunately, these techniques are either of insufficient specificity or are too laborious and technically complex for the routine selective identification and quantification of apoptotic cells *in situ*.

Recent attempts to identify and quantify apoptosis have taken advantage of the internucleosomal fragmentation of DNA which is often linked to, but is not diagnostic for, cell death by apoptosis. Various *in situ* histochemical techniques have been applied to the end-labeling of nicked DNA (Gavrieli et al., J. Cell Biol. 119:493-501 1992; Wijsman et al., J. Histochem. Cytochem. 41:7-12 1993; Wood et al., Neuron 11:621-632 1993). Although these techniques have become popular for marking apoptotic cells *in situ*, it has become recognized recently that DNA fragmentation can also result from cell stress or necrotic degeneration. Consequently, the *in situ* techniques which detect fragmented DNA are not selective in detecting cells undergoing apoptosis (Nitatori et al., J. Neurosci. 15:1001-1011 1995; Lassmann et al., Acta Neuropathol, 89:35-41 1995).

Molecular techniques have also been employed for the detection in cell and tissue extracts of internucleosomal DNA degradation linked to apoptosis (Wyllie, AH, Nature 284:555-556 (1980); Wyllie et al., J. Pathol. 142:67-77 (1984)). The *in situ* and molecular techniques which rely on the detection of internucleosomal DNA

fragmentation are not sufficiently thorough for the detection of apoptotic cell death since they do not detect forms of apoptosis not associated with internucleosomal DNA degradation (Cohen et al., *Biochem. J.* 286:331-334 1992; Schulze-Osthoff et al., *J. Cell Biol.* 127:15-20 1994). Moreover, the molecular methods lack the sensitivity and cellular resolution needed to define the role of apoptosis of particular cell types in disease processes. This is especially true for chronic slow degenerative diseases, in which cell death is protracted and asynchronous, and individual apoptotic cells are present for only a limited period of time.

An increased understanding of the biochemical mechanisms of apoptotic cell death has arisen from recent genetic and cell biological studies. A family of cysteine proteases related to interleukin-1 β converting enzyme (ICE) has been found to play an essential role in the intracellular pathway of apoptosis (reviewed in Martin et al., *Cell* 82:349-352 1995). ICE itself is not a mediator of apoptosis in most mammalian cell types. Rather, a family of homologous proteases comprising at least nine human ICE family proteases have been identified to date (ICE, CPP32/apopain/Yama, ICH-1, TX/ICH-2/ICE_{rel}III, ICE_{rel}III, MH-1/MH-3/ICE-LAP3, Mch2, FLICE/Mch5, ICE-LAP6/Mch6), each of which leads to apoptosis when over-expressed in a proteolytically active form in cultured mammalian cells (Miura et al., *Cell* 75:653-660 1993; Wang et al., *Cell* 78:739-750 1994; Fernandes-Alnemri et al., *J. Biol. Chem.* 269:30761-30764 1994; Faucheu et al., *EMBO J.* 14:1914-22 (1995); Kamens et al., *J. Biol. Chem.* 270:15250-15256 1995, Alnemri et al., *J. Biol. Chem.* 270:4312-4317 1995; Fernandes-Alnemri et al., *Cancer Res.* 55:6045-6052 1995; Lippke et al., *J. Biol. Chem.* 271:1825-1828 1996; Muzio et al., *Cell* 85:817-827 1996; Duan et al., *J. Biol. Chem.* 271:16720-16724 1996). Moreover, treatment of cells with apoptotic stimuli increases ICE-like proteolytic activity in cell extracts (Los et al., *Nature* 375:81-83 1995; Enari et al., *Nature* 380:723-726 1996). Proteolytic activity by ICE homologues is required to initiate apoptosis, since overexpression of mutant, inactive ICE homologues does not lead to apoptosis, and several protease inhibitors of the ICE family block apoptosis (Miura et al., *ibid.*; Gagliardini et al., *Science* 263:826-828 1994; Enari et al., *Nature* 375:78-81 1995; Milligan et al., *Neuron* 15:385-393 1995, Los et al., *ibid.*; Zhivotovsky et al., *Exp. Cell Res.* 221:404-412 1995; Schlegel et al., *J. Biol. Chem.* 271:1841-1844 1996).

Degradation of specific cellular proteins, as would be expected to occur following the activation of an ICE-like protease, has also been associated with apoptosis. For example, poly(ADP-ribose)polymerase (PARP) is cleaved specifically during apoptosis in mammalian cells (Kaufmann et al., Cancer Res, 53:3976-3985
5 1993) and is an excellent substrate *in vitro* for several ICE homologues (Tewari et al., Cell 81:801-809, 1995; Nicholson et al., Nature 376:37-43 1995; Gu et al., J. Biol. Chem. 270:18715-18718, 1995; Fernandes-Alnemri et al., Cancer Res. 55:2737-2742 1995-, Fernandes-Alnemri et al., *ibid.*; Lippke et al., J. Biol. Chem. 271:1825-1828 1996). In the human promyelocytic leukemia cell line HL60 (Collins et al., Nature
10 270:347-349 1977), PARP is degraded in response to incubation with etoposide, which leads to cell death by apoptosis (Kaufmann et al., *ibid.*). Protease inhibitors which block the activity of ICE homologues prevent not only apoptosis, but PARP degradation as well (Schlegel et al., *ibid.*).

Due to the inadequacies in many of the known methods for the detection
15 of cell apoptosis, there continues to be a need for new, selective methods of detection. The present invention is directed to this, as well as other, important ends.

Summary of the Invention

The present invention provides methods for the biochemical and histochemical detection of apoptosis. The methods are based on the use of antibodies
20 which react selectively with fragments of proteins whose degradation is stimulated during apoptosis.

In one embodiment, there is provided a method of detecting apoptosis by using antibodies which bind specifically to peptides or fragments of proteins having the COOH-terminal amino acid sequence SEQ ID NO:1 (GDEVVD) which are generated
25 during apoptosis. The method involves contacting a sample of cells with the antibody, and determining by immunoassay the amount of the antibody which binds to the sample relative to the amount of antibody which binds to a sample known to be free of apoptosis.

Another embodiment provides a method of detecting apoptosis *in situ*
30 based on the use of immunohistochemical staining of cells in a fixed preparation. The preparation may be a culture of cells which have been fixed or a sample of tissue fixed

and sectioned. The fixed preparation is contacted with an antibody prepared against the peptide sequence of SEQ ID NO:2 (CKGDEVD).

In another embodiment of the invention, a first sample of cells containing a protein which generates immunoreactive fragments during apoptosis is exposed to a test compound under conditions or treatment known to trigger apoptosis in the cells. A second sample of the same cells is also placed under conditions known to trigger apoptosis, in the absence of any test compound. A test compound inhibits apoptosis if antibody binding to the first sample is less than antibody binding to the second sample.

In still another embodiment, a first sample of cells is exposed to a test compound. A second sample of the same cells is not exposed to the test compound. A test compound stimulates apoptosis if antibody binding to the first sample is greater than antibody binding to the second sample.

In another embodiment, a candidate compound is administered to a mammal, preferably a rodent such as, for example, a gerbil, mouse, or rat, under conditions known to stimulate apoptosis. The level of apoptosis-generated protein fragments is determined using immunoassays as described above. A compound tests positive as an inhibitor of apoptosis if the amount of apoptosis-generated protein fragments taken from an animal to which the candidate compound had been administered is less than that present in an equivalent sample from an animal exposed to the same apoptosis-stimulating conditions, but not exposed to the candidate compound.

In yet another embodiment, a candidate compound is administered to a mammal, such as a gerbil, mouse, or rat, and the level of apoptosis-generated protein fragments is determined using immunoassays as described above. A compound tests positive as a stimulator of apoptosis if the amount of apoptosis-generated protein fragments taken from an animal to which the candidate compound had been administered is greater than that present in an equivalent sample from an animal not exposed to the candidate compound.

Another embodiment of the present invention is the detection in a subject of disease, disorder, or condition associated with cell apoptosis. A sample of cells is obtained from the subject. The sample is contacted with an antibody against SEQ ID

NO:2. The extent of binding of the antibody with cells in the sample is determined, preferably by immunoassay, relative to a control sample known to be free of apoptosis.

Another embodiment of the present invention is an antibody prepared against the peptide SEQ ID NO:2 (CKGDEVD). The antibody preferably reacts
5 selectively with the about 30 kDa NH₂-terminal polypeptide derivative of poly(ADP-ribose)polymerase produced in cells undergoing apoptosis.

Another embodiment of the present invention is a kit for *in vitro* determination of the level of apoptosis-generated protein fragments in a sample. The kit comprises: (1) a primary antibody capable of binding to protein fragments generated
10 during apoptosis, (2) a secondary antibody conjugated to a signal-producing label, the secondary antibody being one which binds to the primary antibody; alternatively, the secondary antibody binds specifically to an apoptosis-generated protein fragment at an epitope different from that to which the primary antibody binds; and (3) a signal-producing tertiary reagent capable of recognizing a tagged secondary antibody.

15 **Brief Description of the Drawings**

For the purpose of illustrating embodiments of the present invention, there are shown in the drawings certain features. It should be understood, however, that this invention is not limited to the precise embodiments shown.

Figure 1 shows a design of an antibody which reacts selectively with
20 protein fragments generated during apoptosis. The sequence around the site within poly(ADP-ribose)polymerase (PARP) that is cleaved in apoptotic cells is shown at the arrow. The antibodies were designed to react with the COOH-terminal domain of the NH₂ terminal fragment of PARP, and other polypeptides carrying the preferred sequence at their carboxy terminus following cleavage.

Figure 2 shows an immunoblot detection of apoptotic proteolysis in
25 etoposide-treated HL60 cells. Lane 1 - untreated cells; Lane 2 - two hour etoposide treatment; Lane 3 - four hour etoposide treatment. Nuclear extracts prepared from the cells were separated by SDS-PAGE (15 μ g protein per lane) and transferred to nitrocellulose by Western blotting. Polypeptides immunoreactive with Ab127 (1/5,000)
30 were labeled by standard techniques (e.g., Harlow and Lane (1988) *ibid*; Roberts-Lewis et al. (1994) *ibid*). Note that etoposide-treated apoptotic HL60 extracts, but not

extracts from untreated cells, contain an immunoreactive polypeptide of about 30 kDa (arrow), the size expected of the NH₂-terminal fragment of PARP (Lazebnik et al. (1994) *ibid.*) Levels of an immunoreactive polypeptide of approximately 80 kDa also were reproducibly increased in apoptotic cells, whereas faint immunolabeling of an
5 approximately 100 kDa polypeptide was observed regardless of cell treatment.

Figure 3 represents confirmation that the about 30 kDa immunoreactive polypeptide is labeled by Ab127 and is a protein fragment generated during apoptosis. Nuclear extracts (10 μg per lane) were prepared from etoposide-treated apoptotic HL60 cells (lanes 1,3) or untreated cells (lanes 2,4). Extracts from cells not treated with the
10 etoposide were incubated 15 minutes at room temperature with the ICE-like protease recombinant human caspase 3 (rhCPP32). Lanes 1,2 - immunolabeled with Ab127 as described for Figure 2. Lanes 3,4 - immunolabeled with Ab127 that had been preabsorbed with 1.5 μg peptide immunogen (CKGDEVD - SEQ ID NO: 2) per μl antiserum. Note that the immunoreactive about 30 kDa polypeptide in apoptotic cells
15 is also generated by rhCPP32 treatment of a cell extract not treated with etoposide (compare lanes 1 and 2). The immunoreactivity is not observed following preabsorption of the antisense with peptide immunogen (lanes 3, 4).

Figure 4 shows immunoblot detection of apoptotic proteolysis in growth factor-deprived neuronally differentiated PC12 cells. NGF-differentiated PC12 cells
20 were either maintained (+NGF) or withdrawn (-NGF) from growth factor for 24 hours. Nuclear extracts of differentiated PC12 cells (NUC) were incubated with recombinant CPP32 for either 0, 10, or 40 minutes at room temperature. For comparison, a nuclear extract of HL60 cells that had been incubated with CPP32 is also shown. Note that a strong immunoreactive polypeptide of approximately 46 kDa
25 (and a weak one of approximately 35 kDa, not shown in this figure) is detected in NGF-deprived, but not NGF-maintained, PC12 cells. Immunoreactive polypeptides of identical size are formed in PC12 nuclear extracts incubated with recombinant CPP32. The immunoreactive polypeptides are not derived from PARP, since they migrate differentially from the about 30 kDa PARP fragment apparent in the HL60 extract.

30 Figures 5A and 5B show immunohistochemical detection of apoptotic proteolysis in growth factor-deprived neuronally differentiated PC12 cells. PC12 cells either maintained on NGF (5A) or withdrawn from NGF for 24 hours (5B) were

labeled with Ab127 at 1/20,000 using a standard indirect immunoperoxidase technique (e.g., Roberts-Lewis et al. (1994) *ibid.*) Cells were photographed at 200X magnification, 1260X magnification for the insert. Note that Ab127 strongly labels a subset of NGF-deprived cells. The immunostaining took the form of a series of small, intensely labeled puncta which sometimes formed an annulus around the cell. No immunolabeling of NGF-deprived PC12 cells was observed in the absence of Ab127 (data not shown).

Figures 6A-6C show immunohistochemical detection of apoptotic proteolysis in the developing post-natal rat brain. Sagittal sections from aldehyde-fixed rat brain were prepared at 40 μ m on a freezing microtome, and were labeled with Ab127 (1/3,000) using a standard indirect immunoperoxidase technique (Roberts-Lewis et al. (1994) *ibid.*) A - Hippocampal formation, post-natal day 4 (100X magnification); DG - dentate gyrus; CA3 - the CA3 subfield of hippocampus; CA1- the CA1 subfield of hippocampus; S - subiculum. Note the scattered, intensely immunoreactive cells (open arrowheads). At higher magnification, these cells have the morphology of neurons. B - Inferior colliculus, post-natal day 9 (200X magnification). Scattered neurons exhibit intense immunoreactivity in their perikarya and dendritic processes. Note the beaded appearance of the immunolabeled dendrites, indicative of active degeneration. C - Parietal neocortex, post-natal day 9 (100X magnification). Immunoreactivity indicative of apoptotic proteolysis is restricted to a small subset of neurons in layer 2.

Detailed Description of the Invention

As employed above and throughout the disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings.

“Apoptosis” refers to a specific morphological form of cell death characterized by fragmentation of cells and their nuclei into membrane-bound particles. Apoptosis can be triggered by, for example, treatment with compounds such as etoposide, staurosporine, tumor necrosis factor- α , ceramide, and the like, or by conditions such as x-irradiation.

“About” in reference to a numerical value means $\pm 5\%$ of the indicated value. For example, with specific reference to the NH_2 -terminal polypeptide derivative

of PARP, produced in cells undergoing apoptosis, the molecular weight as determined using Western blot under conditions based upon detection with antibodies disclosed herein, is between 30 and 31 kDa, i.e., about 30 kDa. ($30 \pm 5\%$ = a range of between 28.5 and 31.5.)

5 "Apoptosis-generated protein fragment-specific antibody" refers to an antibody that recognizes apoptosis-generated protein fragments but not intact proteins.

"SEQ ID NO:1" refers to the amino acid sequence GDEV D (Gly-Asp-Glu-Val-Asp).

10 "SEQ ID NO:2" refers to the amino acid sequence CKGDEV D (Cys-Lys-Gly-Asp-Glu-Val-Asp).

"Substantially pure" describes a compound which has been separated from other components which naturally accompany it. Typically, a compound is substantially pure when at least 75%, more preferably at least 90%, and most preferably at least 99%, of the total material (by volume, by wet or dry weight, or by
15 mole percent or mole fraction) in a sample is the compound of interest. Purity can be measured by any appropriate method, e.g., in the case of polypeptides by column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis. In particular, a protein is substantially purified when it is separated from the native contaminants which accompany it in its natural state.

20 The terms "reacts selectively" or "binds specifically" describe an antibody that recognizes and binds to target protein fragments, but does not substantially recognize and bind to other molecules, such as intact proteins.

"Etoposide" means a semisynthetic derivative of podophyllotoxin, used as an antineoplastic.

25 "Antineoplastic" means inhibiting the maturation and proliferation of malignant cells.

"Epitope" means a site on the surface of an antigen molecule to which a single antibody molecule binds.

30 "Vehicle" refers to a relatively inert substance added to a bioactive agent in order to confer a suitable consistency or form to the agent.

The present invention is directed, in part, to improved methods for the detection of cell apoptosis. Embodiments of the present invention involve contacting a

sample with an antibody which binds selectively to protein fragments generated during apoptosis. By immunoassay, the amount of the antibody which becomes bound to the target protein fragments is determined, using as comparison a sample known to be free of apoptosis.

5 Poly-ADP-ribose polymerase (PARP) is one of the proteins whose proteolytic degradation is stimulated in a variety of cells undergoing apoptosis (Kaufmann et al., *ibid.*; Lazebnik et al., *Nature* 371:346-347 1994; Tewari et al., *ibid.*). As shown schematically in Figure 1, in apoptotic cells the approximately 115 kDa PARP is preferentially cleaved at a single site, generating an NH₂-terminal
10 fragment of about 30 kDa and a COOH-terminal derivative of approximately 85 kDa (apparent molecular weights as determined by SDS polyacrylamide gel electrophoresis; Kaufmann et al., *ibid.*; Lazebnik et al., *ibid.*). The five residues immediately NH₂-terminal to the cleavage site are completely conserved in PARP from several vertebrate species, whereas the residues immediately COOH-terminal to the cleavage site are
15 divergent (Cherney et al., *Proc. Natl. Acad. Sci. USA* 84:8370-8374 1987; Saito et al., *Gene* 90:249-254 1990; Huppi et al., *Nuc. Acids Res.* 17:3387-3401 1989; Ittel et al., *Gene* 102:157-164 1991; Lazebnik et al., *ibid.*).

Additional peptide fragments are produced in cells undergoing apoptosis. For example, DNA replication complex C, DNA-dependent protein kinase, protein
20 kinase of presenilin 1 and 2, spectrin (fodrin), as well as other polypeptides, are known to be degraded and generate peptide fragments during apoptosis. Antibodies to the peptide fragments of these polypeptides could be prepared in order to identify cells undergoing apoptosis.

We hypothesized that the highly conserved pentapeptide sequence may
25 be critical for recognition by the protease(s) activated during apoptosis -- i.e., be the apoptosis cleavage recognition site -- and an antibody raised to this sequence might react selectively with the about 30 kDa NH₂-terminal derivative of PARP produced in cells undergoing apoptosis (Figure 1). Should the sequence be inaccessible in the intact PARP, or in different PARP derivatives formed during the normal turnover of
30 the protein, then an antibody to the sequence may be expected to be a highly specific probe for apoptotic proteolysis of PARP. Conceivably, the antibody might also react selectively with fragments of proteins other than PARP that also contain the particular

sequence and, therefore, may exhibit enhanced degradation during apoptosis.

We disclose herein antibodies which preferentially bind to protein fragments produced during apoptosis and, thus, confirm our hypothesis concerning the apoptosis cleavage recognition site.

5 Measurement of apoptosis-associated proteolysis levels can be carried out by the use of an immunoassay which allows detection of binding between apoptosis-generated protein fragments and an antibody specific to apoptosis-generated protein fragments. The amount of bound antibody can be determined by detection of enzymic, chromogenic, radioactive, fluorescent or luminescent labels which are
10 attached to either the antibody which binds to the apoptosis-generated protein fragments or to a secondary antibody which recognizes the antibody which binds to the apoptosis-generated protein fragments.

 It is preferred that antibodies for use in the methods of the present invention react selectively with apoptosis-generated protein fragments, and that they do
15 not react with intact protein. An important feature of the present invention is an antibody prepared against the peptide CKGDEVD (SEQ ID NO: 2) that reacts preferentially with the about 30 kDa NH₂-terminal polypeptide derivative of poly(ADP-ribose)polymerase (PARP) produced in cells undergoing apoptosis. This antibody also reacts selectively with fragments of proteins other than PARP, i.e. the approximately
20 46 and approximately 35 kDa polypeptides in apoptotic PC12 cells. However, although different proteins may be degraded in apoptotic cells of different sources, thus generating reactive protein fragments of different size, if the protein fragments contain the COOH-terminal sequence GDEVD (SEQ ID NO:1), they will be detected by the methods of this invention.

25 Substantially pure peptides having the amino acid sequences SEQ ID NO:1 (GDEVD) and SEQ ID NO:2 (CKGCEVD) may be used in generating antibodies which bind with specificity thereto. Antibodies for the particular amino acid sequences described herein may be generated by, for example, immunizing a mammal with the appropriate peptide or peptide conjugate. Methods of generating both monoclonal and
30 polyclonal antibodies which recognize these peptides are described in *Antibodies, A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1988), incorporated herein by reference.

Antibodies which specifically recognize apoptosis-generated protein fragments, but not intact proteins, can be prepared by standard immunization methods using a peptide which correspond to a sequence derived from the about 30 kDa NH₂-terminal fragment of PARP (GDEVD; SEQ ID NO:1) as the immunogen. This

5 peptide can be generated by standard methods known in the art. The NH₂-terminal extension of SEQ ID NO:1 (GDEVD) utilized to make SEQ ID NO:2 (CKGDEVD) can itself be used as an immunogen. Other protein or peptide antigens which, regardless of their origins, length, or degree of homology with naturally occurring apoptosis-generated protein fragments, lead to the production of antibodies which bind

10 specifically to the apoptosis-generated protein fragments, may also be used in the methods of the invention. However, preferred antibodies for use in the methods of the present invention are Ab127 and Ab128. In order to determine the effectiveness of antibodies for use in the methods of the present invention, the reactivities of the antibodies to normally occurring proteins and apoptosis-generated protein fragments are

15 compared. Procedures for such comparison are exemplified herein.

The antibodies can be applied to the detection and measurement of apoptotic proteolysis, to the immunohistochemical tagging and quantification of cells undergoing apoptosis *in vitro* and *in vivo*, and to the identification of agents which stimulate or block apoptosis.

20 The methods of the invention can be used to diagnose cell apoptosis, and associated conditions, in a subject such as a mammal, and in particular a human subject. The methods can be used to determine whether a subject has or is at risk of developing a pathological condition.

The methods of the invention can also be used to diagnose a disease,

25 disorder, or condition which is of either pathological or non-pathological origin including, but not limited to, chronic neurodegenerative disease, cancer, sepsis, trauma, hypoxia, anoxia, ischemia, spinal trauma, head trauma, lesions, and exposure to toxins.

The method of the present invention is also useful for identification of

30 compounds which inhibit or stimulate (e.g., in oncology) apoptotic cell death by determining that the compounds inhibit or stimulate the formation of apoptosis-generated protein fragments. The protein fragments are detected by determining the

extent of binding of an antibody prepared against the peptide sequence of SEQ ID NO:2 (CKGDEVD).

The methods of the present invention can also be used to determine the extent of activity of a candidate compound in decreasing or increasing the apoptotic activity in a mammal.

In association with the methods of the present invention, analysis may be performed on proteins obtained from lysed cells which have been separated by means of SDS-polyacrylamide gel electrophoresis ("PAGE"). The proteins are contacted with a selective antibody and analysis is performed, preferably by immunoassay, to determine the presence of protein fragments which bind to the antibody. Comparison may be made to a control consisting of proteins from similar lysed cells known to be free of apoptosis.

Immunoassays which may be used in the methods of the present invention include, but are not limited to: ELISA, cell-based ELISA, filter-binding ELISA, inhibition ELISA, Western blots, immunoprecipitation, slot or dot blot assays, immunostaining, RIA, scintillation proximity assays, fluorescent immunoassays using antibody conjugates or antigen conjugates of fluorescent substances such as fluorescein or rhodamine, Ouchterlony double diffusion analysis, and immunoassays employing an avidin-biotin or a streptavidin-biotin detection system. Modifications of the known immunoassay techniques may also be used.

It will also be understood by one skilled in the art that any of the immunoassays described above can be used to analyze a tissue sample from a live subject. Possible biological samples for this analysis include blood cells or biopsied cell or tissue samples which can be obtained by standard methods. The levels of apoptosis-generated peptide fragments in the above-described biological samples can be determined in any of the immunoassays described above employing antibodies that bind specifically to the peptide sequence GDEVD (SEQ ID NO:1). The level of apoptosis-generated peptide fragments determined in the biological sample from the subject being analyzed is compared to the level found in an unaffected patient, or in a known standard. This method may be used to diagnose degenerative conditions characterized by abnormal apoptosis. An increase in apoptosis-generated peptide fragments of preferably 50 percent, and more preferably 150 percent, compared to control samples,

may be considered indicative of a degenerative condition.

The above-described diagnostic assays can be facilitated by the use of kits which contain the reagents required for carrying out the assays.

The present invention provides kits which may be used in the detection
5 of cell apoptosis and in the diagnosis of diseases associated therewith. One such kit comprises: (1) a primary antibody capable of binding to protein fragments generated during apoptosis, (2) a secondary antibody conjugated to a signal-producing label, the secondary antibody being one which binds to the primary antibody; and (3) a signal-producing tertiary reagent capable of recognizing a tagged secondary antibody.

10 Another kit that is useful for detection of apoptosis-generated protein fragments according to the present invention includes (1) a first antibody capable of binding to protein fragments generated during apoptosis; and (2) a second antibody conjugated to a signal-producing label, the second antibody also being reactive with an apoptosis-generated protein fragment, but one that binds to a site different from that to
15 which the first antibody binds. This kit is most suitable for carrying out a one or two-antibody immunoassay, e.g., a sandwich ELISA.

In the assay kits provided according to the present invention, the signal-producing label linked to the secondary antibody may be, for example, an enzyme, such as horseradish peroxidase or alkaline phosphatase. Preferably, both the enzyme
20 and the substrate are provided in the kit. The kit may also include an uncoated support onto which a sample to be assayed, or the first antibody, can be immobilized.

The present invention is further described in the following examples. These examples are provided for illustrative purposes only, and are not intended to limit the methods and compositions of the present invention. Other suitable
25 modifications and adaptations of the variety of conditions and parameters normally encountered in immunodiagnostics, apparent to those skilled in the art, are within the scope of the present invention.

EXAMPLES**Example 1: Preparation Of Antibodies Which React Selectively With Protein Fragments Generated During Apoptosis**

Antibodies were prepared by immunizing rabbits with an immunogen
5 comprising the pentapeptide GDEVD (SEQ ID NO:1) and keyhole limpet hemocyanin (KLH). The pentapeptide was directionally conjugated to KLH through NH₂-terminal cysteine-lysine residues (Harlow and Lane (1998) *Antibodies*, Cold Spring Harbor Laboratory, New York, incorporated herein by reference), i.e., as the heptapeptide CKGDEVD (SEQ ID NO:2). The heptapeptide was synthesized by standard solid
10 phase methods, and its structure confirmed by fast atom bombardment-mass spectrometry. It was conjugated to KLH using maleimidobenzoyl-N-hydroxysuccinimide ester (Calbiochem, San Diego, CA). Two rabbits were immunized with the immunogen, and the resultant antisera were collected by standard techniques. The antisera are referred to as Abl27 and Abl28.

15 Example 2: Immunoblotting For Detection Of Apoptosis-Associated Proteolysis In HL60 Cells And Evaluation Of Reactivity Of Abl27 or Abl28 With Apoptosis-Associated About 30 kDa PARP Fragment

HL60 cells (obtained from the American Type Culture Collection, Rockville, MD) were cultured using published techniques (Collins et al., *Nature*,
20 270:347-349 (1977), incorporated herein by reference). Cultures of cells were incubated with either 17 micromolar etoposide (from a 1000X stock solution made in dimethylsulfoxide) to trigger apoptosis or a vehicle. After either 2 or 4 hours, cells were lysed in ice cold 25 millimolar (mM) HEPES (pH 7.5), 5 mM MgCl₂, 0.1 % Triton X-100 and a cocktail of protease inhibitors (1 mM EGTA, 10 micrograms per
25 ml of aprotinin, 10 micrograms per ml of leupeptin, 7 micrograms per ml of pepstatin A, 1 mM phenylmethylsulfonylfluoride (PMSF). The resulting cell lysates were subjected to SDS-polyacrylamide gel electrophoresis on 4 - 20% Tris-glycine gradient gels, and the separated proteins transferred to nitrocellulose membranes by Western blotting. The blots were immunostained with Abl27 (1/5,000) followed by incubation
30 with alkaline phosphatase conjugated goat anti-rabbit IgG (Bio-Rad, Burlingame, CA)

and visualized as described previously (Roberts-Lewis et al., J. Neurosci. 14:3934-3944 (1994), incorporated herein by reference).

As shown in Figure 2, the antibody labeled three polypeptides in the HL60 extracts. Two of the polypeptides were of approximately 100 and approximately 80 kDa molecular weight, and were labeled irrespective of cell treatment, although levels of the approximately 80 kDa polypeptide increased in apoptotic cells. Additionally, Abl27 labeled an about 30 kDa polypeptide which was readily detected only in etoposide-treated, but not in vehicle-treated, cells. The level of the about 30 kDa immunoreactive polypeptide increased with increasing time of cell exposure to etoposide. Stated differently, the antibodies utilized herein did not bind with the approximately 100 kDa polypeptide or the approximately 100 kDa polypeptide to the exclusion of the PARP polypeptide of about 30 kDa.

To control for the specificity of antibody reactivity, preimmune sera and immune sera that were preabsorbed with an excess of the peptide immunogen were also examined. Preimmune sera from the two rabbits did not label the about 30 kDa polypeptide. For preabsorption, Abl27 serum was diluted 50-fold in Tris-buffered saline (pH 7.4), and divided into two aliquots. The peptide CKGDEV D was added to one aliquot at 300 micrograms/ml, and the two aliquots were incubated at room temperature for 1 hour. Next, each aliquot was diluted 100-fold and used for immunoblotting. As shown in Figure 3, immunolabeling of the about 30 kDa polypeptide was blocked by Ab 127 preabsorption.

Example 3: Confirmation That The About 30 kDa Immunoreactive Polypeptide Is A Protein Fragment Generated During Apoptosis

Nuclear extracts of HL60 cells were treated with an enzymatically active preparation of the ICE-like protease CPP32. The baculovirus expression system was used to produce rhCPP32 (Meyer et al., Neurosci. Abstr. 22:565 (1996), incorporated herein by reference) and was demonstrated to be proteolytically active based on cleavage of a synthetic peptide substrate (method described in Nicholson et al., Nature 376:37-43 (1995), incorporated herein by reference). The protease was purified to ~95% homogeneity by chromatography on a Q-Sepharose FF anion exchange resin.

Nuclear extracts were treated with catalytic amounts of the partially purified rhCPP32 and incubated at 23 °C for up to 60 minutes. As shown in Figure 3, incubation with rhCPP32 resulted in an increase in the level of an Abl27 immunoreactive about 30 kDa polypeptide (lane 2). The labeled polypeptide precisely co-migrated with the immunoreactive about 30 kDa polypeptide extracted from intact HL60 cells undergoing apoptosis (lane 1). Preabsorption of the antibody with the peptide CKGDEVD eliminated reactivity with the about 30 kDa polypeptide. The results indicate that the apoptosis-associated degradation of PARP can be specifically detected by an antibody directed at the GDEVD cleavage locus at the COOH-terminus of the about 30 kDa fragment.

Example 4: Use Of Immunoblotting To Detect Apoptotic Proteolysis In Neuron-Like Cells

The cell line PC12 differentiates into a sympathetic neuron-like cell in response to nerve growth factor (NGF), and dies by apoptosis following NGF deprivation (Batistatou et al. (1993) *J. Neurosci.* 13, 4433-4438). A protease inhibitor of the ICE family has been found to reduce the NGF-deprivation induced apoptosis (Troy et al. (1996) *Proc. Natl. Acad. Sci.* 93, 5635-5640). Accordingly, reactivity of Abl27 and Abl28 with polypeptides was compared in NGF-maintained PC12 cells and NGF-deprived apoptotic PC12 cells.

PC12 cells were maintained in NGF-containing medium under low serum conditions (0.18% fetal bovine serum) for 7 days. NGF withdrawal was initiated by three washes with NGF-free culture medium, followed by addition of a neutralizing antibody to NGF (Boehringer Mannheim, Indianapolis, IN). After various time intervals following NGF deprivation, apoptotic cell death was evaluated by measurements of cell survival, internucleosomal DNA fragmentation, and chromatin condensation. Immunoblotting with Abl27 (Figure 4) or Abl28 (data not shown) was performed as described in Example 2 above, and demonstrated that, by 8 hours following NGF deprivation, two immunoreactive polypeptides of approximately 46 and approximately 35 kDa appeared in the cells deprived of NGF (Figure 4). The content of these polypeptides increased with longer periods of NGF deprivation.

Example 5: Confirmation That The Approximately 46 And Approximately 35 kDa Immunoreactive Polypeptides Are Protein Fragments Generated During Apoptosis

Cell-free nuclear extracts of PC12 were incubated with recombinant human CPP32, the ICE-like protease as described in Example 3 for HL60 cell extracts.

- 5 Incubation of nuclear extracts of PC12 cells with CPP32 led to a time-dependent increase in the content of approximately 46 and approximately 35 kDa polypeptides which co-migrated with two immunoreactive species obtained from NGF-differentiated PC12 cells deprived of NGF (Figure 4). Migration of the two polypeptides is distinguishable from the immunoreactive about 30 kDa PARP fragment in apoptotic
- 10 HL60 cells. The results indicate that the approximately 46 and approximately 35 kDa polypeptides represent fragments from proteins other than PARP that contain the GDEVD domain at their COOH-terminus and are specifically generated in PC12 cells undergoing apoptosis. It will be recognized by one skilled in the art that Ab127 or Ab128 may be used for affinity purification of these ICE-like protease substrates and
- 15 their identification by protein microsequencing or mass spectrometry methods.

Example 6: Immunohistochemical Detection Of Cell Death By Apoptosis

NGF-differentiated PC12 cells were grown on chambered microscope slides which had been pre-treated with poly-ornithine and laminin. After 7 days, the culture medium was changed and half of the cultures were deprived of NGF as

- 20 described in Example 4. After 24 hours, cells were processed for immunohistochemistry using Ab127 as follows. Cells were fixed in 2% paraformaldehyde in 0.1 M sodium phosphate buffer, pH 7.4 (60 minutes), and incubated sequentially in 0.09% H₂O₂ in phosphate buffer (20 minutes), followed by 10% normal goat serum/0.5% Triton X-100/Tris-buffered saline (TBS) for 60 minutes.
- 25 Cultures were incubated in TBS alone or TBS containing Ab127 at dilutions from 1/10,000 to 1/40,000 for 2 hours. Following 3 washes in TBS, all cultures were incubated in biotinylated anti-rabbit IgG (Vector, Burlingame, CA) diluted 1/200 in TBS. After 30 minutes, the cultures were washed in TBS and incubated with the avidin-biotin-peroxidase complex (ABC Elite kit, Vector) according to the
- 30 manufacturer's instructions. Following several washes in TBS, color development

was carried out using a standard nickel intensified diaminobenzidine method. After rinsing, cultures of cells were placed under cover slips and photomicrographs were taken using a Nikon Microphot system.

As shown in Figure 5, only very light background staining was observed for Abl27-stained PC12 cells maintained on NGF (Figure 5A). Thus, Abl27 did not react with proteins in healthy PC12 cells that were maintained on NGF. NGF-deprived cells labeled in the absence of the Abl27 primary antibody showed no immunoreactivity. In NGF-deprived cultures, many cells did not label with Abl27 above background, but a subset of cells was intensely immunolabeled (Figure 5B). This specific staining was only observed with Abl27 treatment, and took the form of clusters of darkly stained puncta, which often appeared to form a ring (Figure 5B, insert). The pattern of immunolabeling is similar to the appearance of apoptotic bodies forming from the disintegration of the plasma and nuclear membranes in cells undergoing apoptosis.

Similar results were obtained with other cells. Hippocampal neurons grown in primary culture were stimulated to die by application of the neurotoxic metabolic poison 3-nitropropionic acid. Independent labeling of the cultures with the nuclear stain Hoechst 33258 revealed the presence of apoptotic neurons, with condensed chromatin fragmenting into apoptotic bodies, in the midst of viable cells. When the cultures were immunostained with Abl27, most of the cells were not labeled, but a subset of neurons was intensely immunoreactive. In contrast, no Abl27 immunoreactive cells were found in control cultures that had not been treated with the neurotoxin.

Example 7: Immunohistochemical Labeling Of Apoptosis-Associated Proteolysis In Developing Rat Brain

To examine the use of Abl27 as a probe for identifying cells undergoing apoptosis *in situ*, Abl27 immunohistochemistry was performed on neonatal rats. It has been shown that excess numbers of neurons are formed during early rat brain development, and significant programmed neuronal death occurs by apoptosis during the first 2 post-natal weeks (reviewed in Oppenheim (1991) Annu. Rev. Neurosci. 14,

453-501). To examine the utility of Abl27 in identifying cells undergoing apoptosis *in situ*, Abl27 immunohistochemistry was performed on neonatal rats.

Brains of rats 1, 4, 7 and 9 days of age were fixed in 4% paraformaldehyde, cryoprotected, sectioned in the sagittal plane at 40 micrometers on a sliding microtome, and stained for Abl27 immunoreactivity using a standard indirect immunoperoxidase procedure (described in, e.g., Roberts-Lewis et al., J. Neurosci. 14:3934-3944 (1994), incorporated herein by reference). The Abl27 was used at dilutions ranging from 1/1,000 to 1/50,000. Control sections were processed as described in Roberts-Lewis et al., above, except that the primary antibody (Abl27) was omitted. Following immunostaining, sections were mounted onto glass slides, dehydrated, delipidated, placed under cover slips, and examined and photographed using a Nikon Microphot system.

The immunostaining with Abl27 of the developing rat brain revealed a highly restricted distribution of intensely immunoreactive cells. Nearly all brain cells during the first 10 post-natal days were devoid of Abl27 immunoreactivity. However, groups of cells within specific brain regions and at particular developmental stages were heavily immunopositive.

Figure 6 shows the immunolabeling of subsets of cells in the parietal cortex, hippocampal formation, and inferior colliculus. As shown in Figure 6A, the post-natal day 4 hippocampus contains intensely immunoreactive cells scattered among several subfields. Figure 6B illustrates the heavy immunostaining of neurons of the inferior colliculus at post-natal day 9. The neurons are in an acute stage of degeneration, as manifested by the beaded, fragmented appearance of their dendrites. As shown in Figure 6C, only rare neocortical cells were immunoreactive. In parietal cortex, scattered neurons at an acute stage of degeneration were labeled, almost exclusively in layer 2. At a later stage of development, fewer immunopositive neurons were detected in the neocortex, hippocampus, and other brain regions, consistent with these neurons having the short residence time characteristic for cells dying by apoptosis. However, by post-natal day 9, numerous intense immunopositive cells appeared in the corpus callosum. Their location and morphology identify the immunolabeled cells as oligodendroglia.

No immunolabeling was observed in either neurons or oligodendrocytes

in sections stained in the absence of Abl27. The results confirm and extend the observations reported above for cultured cells, and indicate that an antibody directed at the preferred ICE-homolog proteolytic cleavage site GDEVD may be used to selectively label cells undergoing developmental apoptosis *in situ*.

- 5 All references cited herein are hereby incorporated by reference in their entireties.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANTS: Robert Siman, Donna Bozyczko-Coyne, Sheryl Meyer, Ratan Venkatraman Bhat

(ii) TITLE OF INVENTION: Methods For Detecting Cell Apoptosis

5 (iii) NUMBER OF SEQUENCES: 2

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & Norris LLP

(B) STREET: One Liberty Place - 46th Floor

10 (C) CITY: Philadelphia

(D) STATE: PA

(E) COUNTRY: U.S.A.

(F) ZIP: 19103

(v) COMPUTER READABLE FORM:

15 (A) MEDIUM TYPE: 3.5 inch disk, 1.44 Mb

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: WordPerfect 6.1

(vi) CURRENT APPLICATION DATA:

20 (A) APPLICATION NUMBER: Not Yet Assigned

(B) FILING DATE: Herewith

(C) CLASSIFICATION: N/A

(vii) PRIOR APPLICATION DATA:

25 (A) APPLICATION NUMBER: 60/030,961

(B) FILING DATE: 15-NOV-1996

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Paul K. Legaard

(B) REGISTRATION NUMBER: 38,534

(C) REFERENCE/DOCKET NUMBER: CEPH-0425

30 (ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 215-568-3100

(B) TELEFAX: 215-568-3439

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

35 (A) LENGTH: 5 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

40 Gly Asp Glu Val Asp
1 5

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Cys Lys Gly Asp Glu Val Asp

1

5

What is claimed is:

1. A substantially pure peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2.
2. A substantially pure antibody which binds specifically to an
5 epitope on peptides produced in cells undergoing apoptosis.
3. The antibody of claim 2, wherein said antibody binds specifically to the about 30 kDa NH₂-terminal polypeptide derivative of poly(ADP-ribose)polymerase produced in cells undergoing apoptosis.
4. The antibody of claim 2, wherein said antibody binds specifically
10 to an epitope on a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2.
5. The antibody of claim 4, wherein said antibody binds specifically to an epitope comprising SEQ ID NO:1 on a peptide.
6. The antibody of claim 4, wherein said antibody binds specifically
15 to an epitope comprising SEQ ID NO:2 on a peptide.
7. A method of detecting apoptosis in cells comprising the steps of:
 - (a) contacting a sample of cells with an antibody which binds specifically to an epitope on peptides produced in cells undergoing apoptosis;
 - (b) determining by immunoassay the amount of the antibody which
20 binds to the sample; and
 - (c) comparing the amount of antibody bound in step (b) with the amount of said antibody which binds to a sample known to be free of apoptosis.
8. The method of claim 7 wherein said antibody binds specifically to
25 an epitope on a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2.
9. The method of claim 7 wherein the amount of antibody bound is determined using enzymic, chromogenic, radioactive, fluorescent or luminescent labels which are attached to either said antibody or to a secondary antibody which recognizes said antibody.
- 30 10. The method of claim 9 wherein said immunoassay is selected from the group consisting of ELISA, cell-based ELISA, filter-binding ELISA, inhibition ELISA, Western blots, immunoprecipitation, slot or dot blot assays,

immunostaining, RIA, scintillation proximity assays, fluorescent immunoassays using antibody conjugates or antigen conjugates of fluorescent substances such as fluorescein or rhodamine, Ouchterlony double diffusion analysis, and immunoassays employing an avidin-biotin or a streptavidin-biotin detection system.

5 11. A method of detecting apoptosis in cells or tissue *in situ* comprising the steps of:

 (a) contacting a fixed preparation of said cells or tissue with an antibody which binds specifically to an epitope on peptides produced in cells undergoing apoptosis;

10 (b) determining by immunohistochemical analysis the amount of said antibody which binds to said preparation; and

 (c) comparing said amount of antibody bound with the amount of antibody bound to cells or tissue not undergoing apoptosis.

15 12. The method of claim 11 wherein said antibody binds specifically to an epitope on a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2.

20 13. The method of claim 11 wherein the amount of antibody bound is determined using enzymic, chromogenic, radioactive, fluorescent or luminescent labels which are attached to either said antibody or to a secondary antibody which recognizes said antibody.

 14. The method of claim 11 wherein said cells or tissue include blood cells, biopsied cells, or tissue samples.

 15. A method of diagnosing a disease, disorder, or condition associated with cell apoptosis comprising the steps of:

25 (a) contacting a sample of cells or tissue from a patient with an antibody which binds specifically to an epitope on peptides produced in cells undergoing apoptosis;

 (b) determining by immunoassay the amount of the antibody which binds to the sample; and

30 (c) comparing the amount of antibody bound in step (b) with the amount of said antibody which binds to a sample known to be free of apoptosis.

 16. The method of claim 15 wherein said antibody binds specifically

to an epitope comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2 on a peptide.

17. The method of claim 15 wherein the amount of antibody bound is determined using enzymic, chromogenic, radioactive, fluorescent or luminescent labels
5 which are attached to either said antibody or to a secondary antibody which recognizes said antibody.

18. The method of claim 15 wherein said immunoassay is selected from the group consisting of ELISA, cell-based ELISA, filter-binding ELISA, inhibition ELISA, Western blots, immunoprecipitation, slot or dot blot assays,
10 immunostaining, RIA, scintillation proximity assays, fluorescent immunoassays using antibody conjugates or antigen conjugates of fluorescent substances such as fluorescein or rhodamine, Ouchterlony double diffusion analysis, and immunoassays employing an avidin-biotin or a streptavidin-biotin detection system.

19. The method of claim 15 wherein said disease, disorder, or
15 condition is of a pathological or non-pathological origin.

20. A method of screening compounds to identify inhibitors of apoptosis comprising the steps of:

- (a) exposing a first and second sample of cells containing a protein which generates immunoreactive peptides during apoptosis to conditions known to
20 trigger apoptosis in the cells;
- (b) contacting said first sample with a test compound;
- (c) contacting said first and second samples with an antibody which binds specifically to an epitope on said immunoreactive peptides;
- (d) determining by immunoassay the amount of the antibody which
25 binds to said samples; and
- (e) comparing the amount of antibody bound in said samples;
wherein said test compound inhibits apoptosis if the amount of antibody bound to said first sample is less than the amount of antibody bound to said second sample.

30 21. The method of claim 20 wherein said immunoreactive peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2.

22. The method of claim 20 wherein said condition known to trigger apoptosis is contacting cells with a compound selected from the group consisting of etoposide, TNF- α , ceramide, and staurosporine.

23. The method of claim 20 wherein said condition known to trigger
5 apoptosis is depriving cells of nerve growth factor or exposure to x-irradiation.

24. The method of claim 20 wherein said antibody binds specifically to an epitope comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2 on a peptide.

25. The method of claim 20 wherein the amount of antibody bound is
10 determined using enzymic, chromogenic, radioactive, fluorescent or luminescent labels which are attached to either said antibody or to a secondary antibody which recognizes said antibody.

26. A method of screening compounds to identify inhibitors of apoptosis comprising the steps of:

15 (a) exposing a first and second mammal to conditions known to trigger apoptosis;

(b) administering a test compound to said first mammal;

(c) isolating a cell or tissue sample from said first and second mammals;

20 (d) contacting said samples from said first and second mammals with an antibody which binds specifically to an epitope on peptides produced in cells undergoing apoptosis;

(e) determining by immunoassay the amount of the antibody which binds to said samples; and

25 (f) comparing the amount of antibody bound in said samples;

wherein said test compound inhibits apoptosis if the amount of antibody bound to said sample of said first mammal is less than the amount of antibody bound to said sample of said second mammal.

27. The method of claim 26 wherein said antibody binds specifically
30 to an epitope comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2 on a peptide.

28. The method of claim 26 wherein the amount of antibody bound is

00473649-12009

determined using enzymic, chromogenic, radioactive, fluorescent or luminescent labels which are attached to either said antibody or to a secondary antibody which recognizes said antibody.

29. The method of claim 26 wherein said mammal is a rodent.
- 5 30. A method of screening compounds to identify stimulators of apoptosis comprising the steps of:
- (a) contacting a first sample of cells with a test compound;
 - (b) contacting said first sample and a second sample of cells with an antibody which binds specifically to an epitope on peptides produced in cells

10 undergoing apoptosis;

 - (c) determining by immunoassay the amount of the antibody which binds to said samples; and
 - (d) comparing the amount of antibody bound in said samples;
- 15 wherein said test compound stimulates apoptosis if the amount of antibody bound to said first sample is greater than the amount of antibody bound to said second sample.
31. The method of claim 30 wherein said antibody binds specifically to an epitope comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2.
- 20 32. The method of claim 30 wherein the amount of antibody bound is determined using enzymic, chromogenic, radioactive, fluorescent or luminescent labels which are attached to either said antibody or to a secondary antibody which recognizes said antibody.
33. A method of screening compounds to identify stimulators of
- 25 apoptosis comprising the steps of:
- (a) administering a test compound to a first mammal;
 - (b) isolating cell or tissue sample from said first mammal and from a second mammal not administered said test compound;
 - (c) contacting said samples from said first and second mammals with

30 an antibody which binds specifically to an epitope on peptides produced in cells undergoing apoptosis;

 - (d) determining by immunoassay the amount of the antibody which

binds to said samples; and

- (e) comparing the amount of antibody bound in said samples;
wherein said test compound stimulates apoptosis if the amount of
antibody bound to said sample of said first mammal is greater than the amount of
5 antibody bound to said sample of said second mammal.

34. The method of claim 33 wherein said antibody binds specifically
to an epitope comprising an amino acid sequence selected from the group consisting of
SEQ ID NO:1 and SEQ ID NO:2 on a peptide.

35. The method of claim 33 wherein the amount of antibody bound is
10 determined using enzymic, chromogenic, radioactive, fluorescent or luminescent labels
which are attached to either said antibody or to a secondary antibody which recognizes
said antibody.

36. The method of claim 33 wherein said mammal is a rodent.

37. A kit for determining the amount of apoptosis-generated protein
15 fragments in a biological sample comprising:

(a) a primary antibody which binds specifically to protein fragments
generated during apoptosis; and

(b) a secondary antibody conjugated to a signal-producing label,
wherein said secondary antibody binds specifically to said primary antibody.

- 20 38. The kit of claim 37 wherein said primary antibody binds
specifically to an epitope comprising an amino acid sequence selected from the group
consisting of SEQ ID NO:1 and SEQ ID NO:2 on a peptide.

39. The kit of claim 37 wherein said signal-producing label linked to
said secondary antibody is selected from the group consisting of enzymic,
25 chromogenic, radioactive, fluorescent, and luminescent labels.

40. The kit of claim 37 wherein said signal-producing label linked to
said secondary antibody is an enzyme and said kit further comprises a signal-producing
tertiary reagent which reacts with said enzyme.

41. The kit of claim 40 wherein said enzyme is horseradish
30 peroxidase or alkaline phosphatase.

42. The kit of claim 37 further comprising an uncoated support onto
which a sample to be assayed, or said first antibody, can be immobilized.

43. A kit for determining the amount of apoptosis-generated protein fragments in a biological sample comprising:

(a) a primary antibody which binds specifically to protein fragments generated during apoptosis; and

5 (b) a secondary antibody conjugated to a signal-producing label, wherein said secondary antibody binds specifically to an apoptosis-generated protein fragment at an epitope different from that to which said first antibody binds.

ABSTRACT OF THE DISCLOSURE

Methods for the biochemical and immunohistochemical detection of cell apoptosis are described. The methods utilize the detection and measurement of polypeptide fragments generated during apoptosis. Conditions associated with apoptosis may be detected by the methods of this invention. Methods are also presented for the screening of potential therapeutic compounds which inhibit or stimulate apoptosis. Kits for detection of apoptosis and diagnosis of diseases are also provided.

PROTEIN CLEAVED DURING APOPTOSIS

POLY(ADP-RIBOSE)POLYMERASE (PARP):

NH₂ ————— ······ KGDEVDGVDGVA ······ ————— COOH



ICE-HOMOLOG
CLEAVAGE SITE



~30 kDa



~85 kDa



Ab127

FIGURE 1

FIGURE 2





FIGURE 3



$M_r \times 10^{-3}$




FIGURE 4

09473619-122999

FIGURE 5A

FIGURE 5B



0047361011

FIGURE 6A



00473619-122000

FIGURE 6B

09473610-122099

FIGURE 6C

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled METHODS FOR DETECTING CELL APOPTOSIS, the specification of which

☒ is attached hereto.

☐ was filed on _____ as Application Serial No. _____
and was amended on _____.

☐ was described and claimed in PCT International Application No. _____
filed on _____ and as amended under PCT Article 19 on _____.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information I know to be material to patentability in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose all information I know to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56(a) which became available between the filing date of the prior application and the national or PCT international filing date of this application:

U.S. SERIAL NO.	FILING DATE	STATUS
08/967,625	November 12, 1997	<input checked="" type="checkbox"/> Pending <input type="checkbox"/> Issued <input type="checkbox"/> Abandoned

I hereby claim the benefit under Title 35, United States Code, §119(e)(1) of any United States provisional application(s) listed below:

U.S. SERIAL NO.	FILING DATE	STATUS
60/030,961	November 15, 1996	Abandoned

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: Gary L. Creason, Reg. No. 34,310; J. Peter Fasse, Reg. No. 32,983; John W. Freeman, Reg. No. 29,066; and John F. Hayden, Reg. No. 37,640.

Address all telephone calls to Gary L. Creason at telephone number 617/542-5070.

Address all correspondence to Gary L. Creason, Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110-2804.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both,

COMBINED DECLARATION AND POWER OF ATTORNEY CONTINUED

under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Full Name of Inventor: Robert Siman

Inventor's Signature: _____ Date: _____

Residence Address: 2646 Bittersweet Drive, Wilmington Delaware 19810

Citizen of: United States of America

Post Office Address: 2646 Bittersweet Drive, Wilmington Delaware 19810

Full Name of Inventor: Donna Bozyczko-Coyne

Inventor's Signature: _____ Date: _____

Residence Address: 1703 Flint Hill Road, Landenberg, Pennsylvania 19350

Citizen of: United States of America

Post Office Address: 1703 Flint Hill Road, Landenberg, Pennsylvania 19350

Full Name of Inventor: Sheryl L. Meyer

Inventor's Signature: _____ Date: _____

Residence Address: 274 Level Road, Collegeville, Pennsylvania 19426

Citizen of: United States of America

Post Office Address: 274 Level Road, Collegeville, Pennsylvania 19426

Full Name of Inventor: Ratan Venkatraman Bhat

Inventor's Signature: _____ Date: _____

Residence Address: 145 Whispering Oaks Drive, West Chester, Pennsylvania 19382

Citizen of: India

Post Office Address: 145 Whispering Oaks Drive, West Chester, Pennsylvania 19382